(Q34726233)

4 August 2017

1 reference

title

New therapeutic approaches to treat medullary thyroid carcinoma (English)

1 reference

4 August 2017

Martin Schlumberger

1

1 reference

4 August 2017

Francesca Carlomagno

2

1 reference

4 August 2017

Eric Baudin

3

1 reference

4 August 2017

Jean Michel Bidart

4

1 reference

4 August 2017

Massimo Santoro

5

1 reference

4 August 2017

1 January 2008

1 reference

Nature Clinical Practice Endocrinology and Metabolism

4 August 2017

1 reference

4 August 2017

4

1 reference

4 August 2017

1

1 reference

4 August 2017

22-32

1 reference

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features

4 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Thyroid venous catheterization in the early diagnosis of familial medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Long-term follow-up of patients with medullary carcinoma of the thyroid

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Chemoembolization for liver metastases from medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Mechanisms of drug inhibition of signalling molecules

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Structure and chemical inhibition of the RET tyrosine kinase domain

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

BAY 43-9006 inhibition of oncogenic RET mutants

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Sunitinib: from rational design to clinical efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Radiation combined with antiangiogenic and antivascular agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0717

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0717

1 reference

4 August 2017

1 reference